MORE SCIENCE. LESS COUNTING.

SparkSeven Bio leverages an innovative discovery platform developed to overcome the key challenges in the generation of functional antibodies against G protein-coupled receptors (GPCRs). GPCRs are an important class of drug targets for a wide range of indications, including metabolic disorders. Due to their complex structures and conformational dynamics, developing specific monoclonal antibodies targeting this class of membrane proteins remains challenging for the biotech and pharmaceutical industry.

- Not yet founded -


Vision of SparkSeven Bio:

"Being part of the MAxL community will help us accelerate our mission to develop functional GPCR antibodies for the treatment of diseases with unmet medical need."


The management team of SparkSeven Bio: